

COPY OF PAPERS
ORIGINALLY FILED

PATENT CASE IN01159K1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

A. Saksena *et al.*

Serial No.: 10/052,386

Filed: January 18, 2002

)
) Examiner: Not assigned yet
)
) Group Art Unit: Not assigned yet
)
)
) Atty. Docket No.: IN01159K1

For: **NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF
HEPATITIS C VIRUS**

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145
WO 89/04669
WO 98/17679
WO 98/22496
WO 99/07734
WO 00/09558
WO 00/09543
EP 381 216

Publications:

Pizzi *et al.* (1994) *Proc. Natl. Acad. Sci (USA)* 91:888-892
Failla *et al.* (1996) *Folding & Design* 1:35-42
Kollykhalov *et al.* (1994) *J. Virol.* 68:7525-7533
Komoda *et al.* (1994) *J. Virol.* 68:7351-7357
Landro *et al.* (1997) *Biochem.* 36:9340-9348
Ingallinella *et al.* (1998) *Biochem.* 37:8906-8914
Llinàs-Brunet *et al.* (1998) *Bioorg. Med. Chem. Lett.* 8:1713-1718
Martin *et al.* (1998) *Biochem.* 37:11459-11468
Dimasi *et al.* (1997) *J. Virol.* 71:7461-7469
Martin *et al.* (1997) *Protein Eng.* 10:607-614
Elzouki *et al.* (1997) *J. Hepat.* 27:42-48
BioWorld Today 9(217): 4 (November 10, 1998)
Berenguer *et al.* (1998) *Proc. Assoc. Am. Physicians* 110(2):98-112
Hoofnagle *et al.* (1997) *N. Engl. J. Med.* 336:347
R. Zhang *et al.*, *Analytical Biochemistry*, 270 (1999) 268-275

D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002
W. Han *et al*, *Bioorganic & Biomedical Chem Lett.*, 10 (2000) 711-713
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine
Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4,
Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50th Annual Meeting,
Dallas, Texas, November 5-9, 1999.
L. Hughes, *Org. Reactions*, 42 (1992) 335.
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

All the above-noted documents, along with copies of the references, were submitted in the
IDS and PTO-1449 that Applicant filed for the priority case, IN01159K, Serial No.
09/908,955, filed July 19, 2001. Applicants are, therefore, not sending copies of the
documents again. If, however, the Examiner needs copy of any of the references, the
Examiner is invited to contact the undersigned.

The submission of these documents is not to be presumed as an admission that these
documents are prior art. Since no Office Action has issued on the merits of this case,
Applicants believe that no fee is due at this time. If, however, any fees are due, the Office
may charge such fees to Deposit Account No. 19-0365.

July 30, 2002
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1, 1990
Kenilworth, NJ 07033
Tel: (908) 298-5068
Fax: (908) 298-5388

Respectfully submitted,




Palaiyur S. Kalyanaraman
Attorney for Applicants
Reg. No. 34,634

I hereby certify that this correspondence
is being deposited with the U.S. Postal
Service as First Class Mail in an envelope
addressed to Assistant Commissioner for
Patents, Washington, D.C. 20231 on

July 30, 2002

Palaiyur S. Kalyanaraman
Registered Representative


Signature and Date of Signature

03co

COPY OF PAPERS
ORIGINALLY FILED



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10 052,386	
	Filing Date	January 18, 2002	
	First Named Inventor	SAKSENA, et al	
	Group Art Unit	TBA	
	Examiner Name	TBA	
Total Number of Pages in This Submission	5	Attorney Docket Number	IN01159K1

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) Return Post Card Form 1449
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	SCHERING-PLOUGH CORPORATION PATENT DEPARTMENT, K-6-1-1990 PALAIYUR S. KALYANARAMAN REG. NO. 34, 634
Signature	
Date	July 30, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: July 30, 2002			
Typed or printed name	PALAIYUR S. KALYANARAMAN		
Signature		Date	July 30, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

AUG 06 2002

FORM PTO 449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
IN01159K1SERIAL NO.:
10/052,386INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
SAKSENA, et alFILING DATE:
01/18/2002GROUP:
TBA

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
	AD WO 01 74768	10/11/01	WIPO				
	AE WO 01 40262	06/07/01	WIPO				
	AF WO 00 52032	09/08/00	WIPO				
	AG WO 99 07734	02/18/99	WIPO				
	AH WO 98 17679	04/30/98	WIPO				
	AI						
	AJ						
	AK						
	AJ						
	AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	WEI HAN, et al, "alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors", <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , Vol. 10, No. 8, (2000), pp. 711-713.
AM	LLINAS-BRUNET MONTSE, et al, "Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease", <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , Vol. 8, No. 19, (1998), pp. 2719-2724.
AN	
AO	
AP	
AQ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.